Joint meeting with NeuroImmune Interactions in Health and Disease
June 7-9, 2021 | 9:00AM EDT | 1:00PM UTC | 3:00PM CEST*
*Program is in development and subject to change
Neurodegenerative diseases, such as Alzheimer’s disease (AD) and AD-related disorders (ADRD) are quickly becoming a global burden. The number of diagnosed cases of neurodegenerative diseases is staggering and rising at an alarming rate as the population ages. While it is well-recognized that neurodegenerative diseases are characterized by aberrant protein misfolding and aggregate formation, the mechanisms that initiate or promote proteinopathy in disease-specific neural circuits remain poorly understood. Recent advances in human genetics and genome-wide association study (GWAS) have uncovered several genetic loci that are critical for the pathogenesis of neurodegenerative diseases. Furthermore, technological advances in transcriptomics, proteomics, and metabolomics offer many critical new insights into the disease mechanism, as well as opportunities for the development of novel therapeutics that can reverse or mitigate neurodegeneration. Despite these exciting new developments, there are significant gaps in connecting genetic information with disease mechanism and in harnessing the critical role of glia-neuron interactions to develop therapeutic interventions.
This conference aims to provide an integrated discussion of the latest advances in research and therapeutic development for neurodegenerative diseases. This conference program will focus on the roles of genetic risk factors and their contributions to glial and neuronal health in the aging brain, the biophysical properties of protein misfolding and the propagation of disease-specific proteinopathy, the role of intracellular vesicular trafficking in disease pathogenesis, new insights into the diverse role of glia, innate immunity and microbiomes in neurodegeneration, and novel therapeutic approaches that specifically target each of the novel biological areas. It is anticipated that this conference will stimulate more discussions and promote new collaborations among scientists in the academia and industry that ultimately lead to new therapeutic targets to combat neurodegenerative diseases.
Regular Registration Rate: $275 USD
Student Registration Rate: $150 USD
Abstract Submission
‣ For Short Talk Consideration: April 26, 2021
‣ For ePoster Presentation: May 24, 2021
Final ePoster / SciTalk Submission: May 27, 2021
Financial Aid Application: May 24, 2021
*Abstract submission is required in order to submit an ePoster and/or Scitalk
#VKSNeurodegen21
Graduate students and postdoctoral fellows, as well as individuals from low- and middle-income countries (all career stages) working in science and medicine-related fields, are eligible to apply for a FREE registration code.
Find out more about financial aid opportunities here!
Showcase your work to global audiences on the eSymposia platform!
Submit your abstract by the Short Talk Deadline for the opportunity to be selected for a short talk presentation alongside field leaders on the meeting program!
ePoster presenters will be provided with their own dedicated abstract listing on the event website to display their work in multiple formats, and interact with meeting participants. ePoster features include:
To submit your work for an ePoster presentation, and to be considered for short talk selection, go to the “Submit an Abstract” tab on the event homepage.
Christopher K. Glass, MD, PhD
University of California, San Diego
Akiko Iwasaki, PhD
HHMI/Yale University School of Medicine
Mathew M. Blurton-Jones
University of California, Irvine, USA
Anne Brunet
Stanford University, USA
Beverly L. Davidson
Children’s Hospital of Philadelphia and University of Pennsylvania, USA
Valina L. Dawson
Johns Hopkins University School of Medicine, USA
Philip L. De Jager
Columbia University Medical Center, USA
Ádám Dénes
Hungarian Academy of Sciences, Hungary
Fred H. Gage
The Salk Institute for Biological Studies, USA
Christopher K. Glass
University of California, San Diego, USA
Alison Goate
Icahn School of Medicine at Mount Sinai, USA
Michael T. Heneka
German Center for Neurodegenerative Diseases, Germany
Akiko Iwasaki
HHMI/Yale University School of Medicine, USA
Holly Kordasiewicz
Ionis Pharmaceuticals, USA
Virginia M. Y. Lee
University of Pennsylvania School of Medicine, USA
Joseph W. Lewcock
Denali Therapeutics, USA
Marco Prinz
University of Freiburg, Germany
Anne Schaefer
Mount Sinai School of Medicine, USA
Sjors Scheres
MRC Laboratory of Molecular Biology, UK
Lorenz Studer
Memorial Sloan Kettering Cancer Center, USA
Charlotte J. Sumner
Johns Hopkins School of Medicine, USA
J. Paul Taylor
St. Jude Children's Research Hospital, USA
Hui-Hsin Tsai
Biogen, USA
Li-Huei Tsai
Massachusetts Institute of Technology, USA
Jennifer Yokoyama
University of California, San Francisco, USA
Funding for this conference was made possible (in part) by 1R13AG072818-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
The views expressed in this eSymposia are those of the participants and not necessarily of the participants’ organizations or of Keystone Symposia.
This new virtual meeting format came out of difficult circumstances, but your commitment to scientific progress is what inspired us to launch Keystone eSymposia. In these virtual meetings, we are capturing the same innovative essence of our in-person meetings that you've all created as a scientific community. Here, Debbie Johnson, our CEO, explains how we're going to do that.
